As of 2025-10-31, the Intrinsic Value of Kinnate Biopharma Inc (KNTE) is -11.94 USD. This KNTE valuation is based on the model Peter Lynch Fair Value. With the current market price of 2.65 USD, the upside of Kinnate Biopharma Inc is -550.59%.
Based on its market price of 2.65 USD and our intrinsic valuation, Kinnate Biopharma Inc (KNTE) is overvalued by 550.59%.
Note: result may not be accurate due to the invalid valuation result of Peter Lynch's fair value model.
| Range | Selected | Upside | |
| a | |||
| Fair Value | -11.94 - -11.94 | -11.94 | -550.59% |
| P/E | (57.55) - (57.55) | (61.91) | -2436.3% |
| DDM - Stable | (15.01) - (48.90) | (31.95) | -1305.8% |
| DDM - Multi | (12.20) - (33.01) | (18.06) | -781.6% |
| Market Cap (mil) | 125.00 |
| Beta | 3.98 |
| Outstanding shares (mil) | 47.17 |
| Enterprise Value (mil) | 68.00 |
| Market risk premium | 4.60% |
| Cost of Equity | 11.77% |
| Cost of Debt | 5.00% |
| WACC | 7.72% |